Cite
Combination Therapy With Tofacitinib and IL-12/23, IL-23, or IL-17A Inhibition for the Treatment of Refractory Psoriatic Arthritis: A Case Series.
MLA
Shurey, Megan, et al. “Combination Therapy With Tofacitinib and IL-12/23, IL-23, or IL-17A Inhibition for the Treatment of Refractory Psoriatic Arthritis: A Case Series.” JRC: Journal of Clinical Rheumatology, vol. 28, no. 2, Mar. 2022, pp. e626–28. EBSCOhost, https://doi.org/10.1097/RHU.0000000000001767.
APA
Shurey, M., Yip, A., Ziouzina, O. F., Chan, J. F., Dutz, J. P. F., Ziouzina, O., Chan, J., & Dutz, J. P. (2022). Combination Therapy With Tofacitinib and IL-12/23, IL-23, or IL-17A Inhibition for the Treatment of Refractory Psoriatic Arthritis: A Case Series. JRC: Journal of Clinical Rheumatology, 28(2), e626–e628. https://doi.org/10.1097/RHU.0000000000001767
Chicago
Shurey, Megan, Ashley Yip, Olga FRCPC Ziouzina, Jonathan FRCPC Chan, Jan P. FRCPC Dutz, Olga Ziouzina, Jonathan Chan, and Jan P Dutz. 2022. “Combination Therapy With Tofacitinib and IL-12/23, IL-23, or IL-17A Inhibition for the Treatment of Refractory Psoriatic Arthritis: A Case Series.” JRC: Journal of Clinical Rheumatology 28 (2): e626–28. doi:10.1097/RHU.0000000000001767.